

Yumin Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1553698/publications.pdf>

Version: 2024-02-01

38
papers

549
citations

840776

11
h-index

713466

21
g-index

41
all docs

41
docs citations

41
times ranked

673
citing authors

#	ARTICLE	IF	CITATIONS
1	LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1295-1311.	2.5	4
2	A nomogram prediction of pressure injury in critical ill patients: A retrospective cohort study. <i>International Wound Journal</i> , 2022, 19, 826-833.	2.9	7
3	Integrated Analysis of Multi-Omics Data to Identify Prognostic Genes for Pancreatic Cancer. <i>DNA and Cell Biology</i> , 2022, , .	1.9	2
4	CircRAPGEF5 Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the miR-1236-3p/ZEB1 Axis and Serves as a Potential Biomarker. <i>International Journal of Biological Sciences</i> , 2022, 18, 2116-2131.	6.4	12
5	LncRNA RP3-326113.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13. <i>Cell Cycle</i> , 2022, , 1-15.	2.6	5
6	Low level EFCAB1 promoted progress by upregulated DNMT3B and could be as a potential biomarker in lung adenocarcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24166.	2.1	2
7	Low level gastrokine 2 promoted progress of NSCLC and as a potential biomarker. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24213.	2.1	1
8	Differential expression and analysis of extrachromosomal circular DNAs as serum biomarkers in lung adenocarcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24425.	2.1	12
9	Super enhancer lncRNA SENCN promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24460.	2.1	7
10	ADH1C Facilitates Cisplatin Resistance of Lung Adenocarcinoma Cells. <i>DNA and Cell Biology</i> , 2022, 41, 631-640.	1.9	6
11	Constructing a 10 core genes panel for diagnosis of pediatric sepsis. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23680.	2.1	9
12	High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma. <i>PeerJ</i> , 2021, 9, e11697.	2.0	4
13	Critically Ill vs. Non-Critically Ill Patients With COVID-19 Pneumonia: Clinical Features, Laboratory Findings, and Prediction. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 550456.	3.9	5
14	Distribution and reference interval establishment of neutral lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) in Chinese healthy adults. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23935.	2.1	24
15	Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma. <i>Cancer Cell International</i> , 2021, 21, 505.	4.1	9
16	Identification of dyslipidemia as a risk factor for sudden sensorineural hearing loss: A multicenter case-control study. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24067.	2.1	11
17	Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23091.	2.1	4
18	lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-18.	1.9	1

#	ARTICLE	IF	CITATIONS
19	miR-196b-5p mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4347-4357.	7.1	95
20	Analysis of lncRNA UCA1 related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23312.	2.1	9
21	Low expression of PRKDCBP promoted cisplatin resistance in lung adenocarcinoma by DNMT1 and TNFα. <i>Oncology Reports</i> , 2020, 44, 1616-1626.	2.6	4
22	Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small cell lung cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22943.	2.1	7
23	Reduced Vitamin D Levels are Associated with Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 2305-2314.	2.9	12
24	lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 4257-4266.	1.9	31
25	Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. <i>Genes</i> , 2018, 9, 32.	2.4	7
26	Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22576.	2.1	8
27	lncRNA LINC01512 Promotes the Progression and Enhances Oncogenic Ability of Lung Adenocarcinoma. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3102-3110.	2.6	20
28	Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, e22106.	2.1	16
29	Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 14, 5046-5050.	1.8	10
30	Low Expression lncRNA TUBA4B is a Poor Predictor of Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 265-270.	1.9	32
31	Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. <i>BioMed Research International</i> , 2017, 2017, 1-14.	1.9	13
32	Low expression lncRNA RPLPOP2 is associated with poor prognosis and decreased cell proliferation and adhesion ability in lung adenocarcinoma. <i>Oncology Reports</i> , 2016, 36, 1665-1671.	2.6	10
33	Detection and Analysis of Wnt Pathway Related lncRNAs Expression Profile in Lung Adenocarcinoma. <i>Pathology and Oncology Research</i> , 2016, 22, 609-615.	1.9	18
34	Detection of long-chain non-encoding RNA differential expression in non-small cell lung cancer by microarray analysis and preliminary verification. <i>Molecular Medicine Reports</i> , 2015, 11, 1925-1932.	2.4	17
35	Long Noncoding RNA Expression Profiles of Lung Adenocarcinoma Ascertained by Microarray Analysis. <i>PLoS ONE</i> , 2014, 9, e104044.	2.5	78
36	lncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis. <i>Medical Oncology</i> , 2014, 31, 137.	2.5	26

#	ARTICLE	IF	CITATIONS
37	Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression. <i>Oncology Letters</i> , 2014, 8, 813-818.	1.8	10
38	Preliminary study of the level of visfatin and the relationship with insulin resistance in Chinese patients with chronic hepatitis C. <i>Archives of Iranian Medicine</i> , 2013, 16, 74-7.	0.6	1